Arterial Hypertension Induced by Erythropoietin and Erythropoiesis-Stimulating Agents (ESA)
The DOI matches its Crossref record; 87 of the 88 references it cites were found in a registry or an index.
Abstract
This review summarizes the evidence for a hypertensinogenic effect of Erythropoietin (Epo) in normal human subjects and predialysis, hemodialysis, and continuous ambulatory peritoneal dialysis (CAPD) patients. The possible mechanisms of Epo-induced hypertension are examined with in vivo animal and in vitro data, as well as pathophysiological human studies in both normal subjects and CKD patients. The evidence for a hypertensinogenic effect of erythropoiesis-stimulating agents (ESAs) in normal subjects, predialysis CKD, hemodialysis, and CAPD patients is compelling. Epo increases BP directly and notably independently of its erythropoietic effect and its effect on blood rheology. The potential for the development of future agents that might act as specific stimulators of erythropoiesis, devoid of direct hemodynamic side effects is underscored.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NSAIDs can antagonize the effects of RAAS-inhibitors and beta blockers”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [41]
In the citing paper
“No increase in blood pressure with aspirin”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [41]
In the citing paper
“3/1 mm Hg increase with nonselective NSAIDs”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [41]
In the citing paper
“No difference or an increase of up to 3/1 mm Hg with celecoxib”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [41]
In the citing paper
“Increased odds ratio of 3.19 of hypertension with tricyclic antidepressant”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [41]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Correction of anemia with epoetin alfa in chronic kidney disease
Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., & Reddan, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065485 · Cited by 2,762 · cited 9×
“Epo treatment showed a trend to an increased risk for hypertensive AEs by 26% as compared with no Epo/placebo, but the effect was not statistically significant.”
BackgroundInfluentialNormalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia
Drüeke, T. B., Locatelli, F., Clyne, N., Eckardt, K.-U., Macdougall, I. C., Tsakiris, D., Burger, H.-U., & Scherhag, A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062276 · Cited by 2,104 · cited 10×
“Epo treatment showed a trend to an increased risk for hypertensive AEs by 26% as compared with no Epo/placebo, but the effect was not statistically significant.”
BackgroundInfluentialEschbach, J. W., Abdulhadi, M. H., Browne, J. K., Delano, B. G., Downing, M. R., Egrie, J. C., Evans, R. W., Friedman, E. A., Graber, S. E., Haley, N. R., et al. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-12-992 · Cited by 795 · cited 1×
“magnitude of the Epo-induced increase in BP (32).”
BackgroundStroke risk profile: adjustment for antihypertensive medication. The Framingham Study.
D'Agostino, R. B., Wolf, P. A., Belanger, A. J., & Kannel, W. B. (1994) · Stroke · doi:10.1161/01.str.25.1.40 · Cited by 712
Phrommintikul, A., Haas, S. J., Elsik, M., & Krum, H. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60194-9 · Cited by 638 · cited 1×
“Recently, another meta-analysis (24) reported the hypertension AEs in controlled trials that targeted high versus low blood Hb values and included trials previously included in a metaanalysis (21).”
BackgroundSecondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomes
Szczech, L. A., Barnhart, H. X., Inrig, J. K., Reddan, D. N., Sapp, S., Califf, R. M., Patel, U. D., & Singh, A. K. (2008) · Kidney International · doi:10.1038/ki.2008.295 · Cited by 526
Parfrey, P. S., Foley, R. N., Wittreich, B. H., Sullivan, D. J., Zagari, M. J., & Frei, D. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004121039 · Cited by 373 · cited 2×
“One Hb target-controlled trial (41) did not find”
BackgroundHealth centres of today; Finsbury, Peckham.
STEWART, A. B., & Williamson, G. S. (1946) · PubMed · Cited by 256
Revicki, D. A., Brown, R. E., Feeny, D. H., Henry, D., Teehan, B. P., Rudnick, M. R., & Benz, R. L. (1995) · American Journal of Kidney Diseases · doi:10.1016/0272-6386(95)90122-1 · Cited by 254 · cited 1×
“96) Revicki 1995 (91) Predialysis 4/40 11/43 16.”
Casati, S., Passerini, P., Campise, M. R., Graziani, G., Cesana, B., Perisic, M., & Ponticelli, C. (1987) · BMJ · doi:10.1136/bmj.295.6605.1017 · Cited by 242
Cited by
2020 International Society of Hypertension Global Hypertension Practice Guidelines
Unger, T., Borghi, C., Charchar, F., Khan, N. A., Poulter, N. R., Prabhakaran, D., Ramirez, A., Schlaich, M., Stergiou, G. S., Tomaszewski, M., et al. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15026 · Cited by 4,132
2020 International Society of Hypertension global hypertension practice guidelines
Unger, T., Borghi, C., Charchar, F., Khan, N. A., Poulter, N. R., Prabhakaran, D., Ramirez, A., Schlaich, M., Stergiou, G. S., Tomaszewski, M., et al. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002453 · Cited by 1,283
Red Blood Cell Function and Dysfunction: Redox Regulation, Nitric Oxide Metabolism, Anemia
Kuhn, V., Diederich, L., Keller, T. C. S., Kramer, C. M., Lückstädt, W., Panknin, C., Suvorava, T., Isakson, B. E., Kelm, M., & Cortese-Krott, M. M. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6954 · Cited by 469
“Indeed, it was shown that EPO administration to normovolemic anemic patients increased systemic vascular resistance and arterial blood pressure and decreased cardiac output due to diminished heart rate and venous return (103, 194).”
Provenzano, R., Besarab, A., Sun, C. H., Diamond, S. A., Durham, J. H., Cangiano, J. L., Aiello, J. R., Novak, J. E., Lee, T., Leong, R., et al. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06890615 · Cited by 290
“6% of treated patients) was below what has been reported for similar patient populations treated with ESAs (16%–32%) (35,36) and comparable with placebo rates seen in other similar studies in this patient population (37).”
Sarafidis, P. A., Persu, A., Agarwal, R., Burnier, M., de Leeuw, P., Ferro, C. J., Halimi, J.-M., Heine, G. H., Jadoul, M., Jarraya, F., et al. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw433 · Cited by 229
Metadata
- Authors
- Krapf, R., & Hulter, H. N.
- Affiliations
- University of Basel (CH)
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2009-02
- Volume
- 4
- Issue
- 2
- Pages
- 470-480
- ISSN
- 1555-9041 (ISSN-L)
- OpenAlex
- W2130991130
- Cited by
- 180
- References
- 88
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 4 · 2023: 7 · 2022: 10 · 2021: 12 · 2020: 7 · 2019: 11 · 2018: 13 · 2017: 10 · 2016: 14 · 2015: 9 · 2014: 13 · 2013: 15 · 2012: 8
- FWCI
- 10.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Journal of the American Society of Nephrology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Keywords
- erythropoietin, erythropoiesis-stimulating agents, hypertension, hemodialysis, continuous ambulatory peritoneal dialysis, chronic kidney disease, blood pressure, hemorheology, erythropoiesis
- MeSH terms
- Anemia, Animals, Arteries, Blood Pressure, Chronic Disease, Erythropoietin, Hematinics, Renal Dialysis, Humans, Hypertension, Kidney Diseases, Peritoneal Dialysis, Continuous Ambulatory, Risk Assessment, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Arterial Hypertension Induced by Erythropoietin and Erythropoiesis-Stimulating Agents (ESA). https://app.cochat.ai/papers/10.2215/cjn.05040908
- The paper
- Krapf, R., & Hulter, H. N. (2009). Arterial Hypertension Induced by Erythropoietin and Erythropoiesis-Stimulating Agents (ESA). Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.05040908
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.